Purdue Pharma has obtained approval from the US Food and Drug Administration (FDA) for the launch of a new 15mcg/hr dosage strength of Butrans (buprenorphine) Transdermal System CIII. Following the approval, Butrans will be available in ...
Tags: Pain Drug, Purdue Pharma
US-based specialty pharmaceutical firm Upsher-Smith Laboratories will launch the generic version of its Morphine Sulfate extended-release (ER) capsules, CII on 4 September 2013. Morphine Sulfate ER Capsules, CII are currently available in ...
Tags: ER Capsules, pharmaceutical
The upgrade allows improves the performance of the printheads and is available in reel-to-reel or inline formats. The product targets the pharmaceutical sector and the system offers full digital four-colour print. “Variations in ...
Novartis has obtained the US Food and Drug Administration (FDA) approval for a new 13.3 mg/24 h dosage strength of its Exelon Patch (rivastigmine transdermal system), designed to treat patients with mild to moderate Alzheimer's disease. ...
Tags: Alzheimer's disease, Novartis Pharmaceuticals, Exelon Patch
Baxter International has received the US Food and Drug Administration (FDA) approval for its 4000 IU dosage strength of Advate[Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method]. Advate is a full-length recombinant factor ...
Tags: FDA, Baxter hemophilia drug, dosage strength